Evidence map›Paper›PMID 26809466›Full record

ArticleFrontiers of medicine2016

Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma.

Zhi Xu, Chunxiang Cao, Haiyan Xia, Shujing Shi, Lingzhi Hong, Xiaowei Wei, Dongying Gu, Jianmin Bian, Zijun Liu, Wenbin Huang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Frontiers of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Potentiality of Protein phosphatase MgJournal of clinical laboratory analysis · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Zhi XuDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. michelle.xuzhi@hotmail.com.
Chunxiang CaoDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Haiyan XiaDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Shujing ShiDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Lingzhi HongDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Xiaowei WeiDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Dongying GuDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Jianmin BianDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Zijun LiuDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Wenbin HuangDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Yixin ZhangDepartment of General Surgery, Nantong Tumor Hospital, Nantong, 226361, China.
Song HeDepartment of Pathology, Nantong Tumor Hospital, Nantong, 226361, China.
Nikki Pui-Yue LeeDepartment of Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Jinfei ChenDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. jinfeichen@sohu.com.
Nanjing Medical University · CNNantong Tumor Hospital · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a lethal liver malignancy worldwide. In this study, we reported that protein phosphatase magnesium-dependent 1δ (PPM1D) was highly expressed in the majority of HCC cases (approximately 59%) and significantly associated with high serum α-fetoprotein (AFP) level (P = 0.044). Kaplan- Meier and Cox regression data indicated that PPM1D overexpression was an independent predictor of HCCspecific overall survival (HR, 2.799; 95% CI, 1.346-5.818, P = 0.006). Overexpressing PPM1D promoted cell viability and invasion, whereas RNA interference-mediated knockdown of PPM1D inhibited proliferation, invasion, and migration of cultured HCC cells. In addition, PPM1D suppression by small interfering RNA decreased the tumorigenicity of HCC cells in vivo. Overall, results suggest that PPM1D is a potential prognostic marker and therapeutic target for HCC.

Indexed as

alpha-FetoproteinsAnimalsBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorFemaleGene Knockdown TechniquesHumansLiver NeoplasmsMaleMice, Inbred BALB CMiddle AgedNeoplasm InvasivenessNeoplasm TransplantationPrognosisProtein Phosphatase 2Calpha-FetoproteinsBiomarkers, TumorPPM1D protein, humanProtein Phosphatase 2CRNA, Small Interferinghepatocellular carcinomaPPM1Dprognosistarget therapy

Identifiers

PMID26809466
OpenAlexW2263113382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.